Elsevier and JAMA Network sign strategic content agreement for ClinicalKey AI

Elsevier, a global leader in advanced information and analytics, today announced a strategic content agreement with the JAMA Network that brings full-text content and visuals from the JAMA Network Family of Journals to ClinicalKey AI, the company’s clinical grade AI workspace. The addition of the JAMA Network’s specialty journals further deepens a content collection that already spans leading journals and medical society publications worldwide, giving clinicians full-text access to more than half of the world’s top 100 medical journals.

Under the agreement, all published full-text content and visuals from 13 journals — including JAMA, JAMA Network Open and 11 specialty journals (JAMA Cardiology, JAMA Dermatology, JAMA Health Forum, JAMA Internal Medicine, JAMA Neurology, JAMA Oncology, JAMA Ophthalmology, JAMA Otolaryngology–Head & Neck Surgery, JAMA Pediatrics, JAMA Psychiatry and JAMA Surgery) — will inform the responses clinicians receive through ClinicalKey AI.

Clinicians face growing volumes of published evidence and reduced time in which to apply clinical insights. ClinicalKey AI is designed to close that gap by grounding every answer in peer-reviewed, evidence-based sources and linking clinicians directly to the full-text articles behind it.

Omry Bigger, President, Clinical Solutions, Elsevier, said: “Clinicians tell us that trust is the deciding factor in whether they will use AI at the point of care. This strategic content agreement with the JAMA Network means that when a clinician uses ClinicalKey AI, the answer can draw on many years of prestigious evidence-based content from JAMA journals without compromising privacy and security. We look forward to our strong collaboration with the JAMA Network and bringing the best insights and clinical content directly into the hands of clinicians at the point of care.”

Brian Shields, Group Vice President and Publisher of JAMA and the JAMA Network said: “The research published across the JAMA Network is intended to help inform clinical decisions at the bedside, in the clinic and in the exam room, Working with a global information and analytics leader like Elsevier extends the reach of that evidence to clinicians in the moments they need it most, with the full article always a click away so they can see the study, the methods and the context behind any answer.”

Built for health systems

ClinicalKey AI is deployed by health systems that require both credible content, precision AI and enterprise-grade technology. Access to JAMA Network journals and other evidence-based information is delivered securely and compliantly, with capabilities including:

• API-based integration options, including compatibility with existing workflow tools.

• Support for HIPAA-compliant use in North America, with privacy and security controls built to help protect patient health information (PHI).

• A new deep research assistant that allows clinicians to take a deeper dive into clinical topics.

• Multi-language support and prompt sharing.

• Coming soon: Following the recent acquisition of WellSheet, ClinicalKey AI will offer deeper integration into hospital systems’ electronic health records to deliver patient context and trusted clinical information to clinicians.

Content from the JAMA Network journals is available to ClinicalKey AI customers now.

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업이다. 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔다. 전 세계 170개국에서 학계 및 기업 연구 커뮤니티와 의사, 간호사, 미래 의료 전문가, 교육자들이 수행하는 중요한 업무를 지원한다. 세계 최고 수준의 근거 기반 과학·의학 콘텐츠와 정밀 AI, 전문가 평가를 토대로 구축한 연구 및 임상 등급 솔루션을 제공하여 의미 있는 변화를 만들어가는 사람들에게 더 나은 성과를 거둘 수 있도록 돕는다. 또한 포용성과 지속가능성 증진에 앞장서며 엘스비어가 지원하는 커뮤니티와 협력한다. 엘스비어 재단(The Elsevier Foundationopens in new tab/window)은 전 세계의 연구 및 보건 파트너십을 지원한다.

엘스비어는 전문가 및 기업 고객에게 정보 기반 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원이다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아볼 수 있다.